@article{article, title  = {{A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2021}},

 month = {{2}},

 author = {{Powles T and Meeks JJ and Galsky MD and Van Der Heijden MS and Nishiyama H and Al-Ahmadie HA and Goluboff ET and Hois S and Donegan SE and Williams V and Xiao F et al}},

 doi = {{10.1200/jco.2021.39.6_suppl.tps505}},

 volume = {{39}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{TPS505-TPS505}},

 note = {{Accessed on 2024/12/22}}}